Last reviewed · How we verify
HZ/su
HZ/su is a recombinant zoster vaccine that stimulates immune responses against varicella-zoster virus to prevent herpes zoster (shingles) and post-herpetic neuralgia.
HZ/su is a recombinant zoster vaccine that stimulates immune responses against varicella-zoster virus to prevent herpes zoster (shingles) and post-herpetic neuralgia. Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of herpes zoster and post-herpetic neuralgia in immunocompromised adults.
At a glance
| Generic name | HZ/su |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Recombinant subunit vaccine with adjuvant |
| Target | Varicella-zoster virus glycoprotein E (gE) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
HZ/su combines a recombinant varicella-zoster virus glycoprotein E antigen with an AS01B adjuvant system to enhance immunogenicity. The vaccine triggers both CD4+ and CD8+ T-cell responses as well as antibody production, providing durable protection against reactivation of latent varicella-zoster virus infection that causes shingles in older adults and immunocompromised populations.
Approved indications
- Prevention of herpes zoster (shingles) in adults aged 50 years and older
- Prevention of herpes zoster and post-herpetic neuralgia in immunocompromised adults
Common side effects
- Injection site pain
- Injection site redness
- Injection site swelling
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators (PHASE4)
- A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant (PHASE1, PHASE2)
- Safety of the Herpes Zoster Subunit Vaccine in Lupus (PHASE4)
- A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults (PHASE3)
- Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster (PHASE3)
- Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
- A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults (PHASE3)
- A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HZ/su CI brief — competitive landscape report
- HZ/su updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI